Trial: 202001136

PEPN1812 – A Phase I Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Phase

I

Principal Investigator

Hayashi, Robert

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov